Comparing Stoke Therapeutics (NASDAQ:STOK) and MannKind (NASDAQ:MNKD)

MannKind (NASDAQ:MNKD) and Stoke Therapeutics (NASDAQ:STOK) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, profitability, analyst recommendations, institutional ownership, dividends, valuation and earnings.

Risk and Volatility

MannKind has a beta of 1.1, indicating that its stock price is 10% more volatile than the S&P 500. Comparatively, Stoke Therapeutics has a beta of 1.36, indicating that its stock price is 36% more volatile than the S&P 500.

Institutional & Insider Ownership

49.5% of MannKind shares are held by institutional investors. 2.6% of MannKind shares are held by insiders. Comparatively, 9.6% of Stoke Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares MannKind and Stoke Therapeutics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MannKind	$413.37 million	3.24	$5.86 million	($0.23)	-18.09
Stoke Therapeutics	$184.42 million	9.29	-$6.89 million	($3.77)	-6.95

MannKind has higher revenue and earnings than Stoke Therapeutics. MannKind is trading at a lower price-to-earnings ratio than Stoke Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares MannKind and Stoke Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
MannKind	-18.10%	N/A	-10.01%
Stoke Therapeutics	-862.07%	-67.30%	-58.52%

Analyst Recommendations

This is a breakdown of recent recommendations for MannKind and Stoke Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MannKind	1	2	7	0	2.60
Stoke Therapeutics	1	0	10	0	2.82

MannKind presently has a consensus target price of $8.50, suggesting a potential upside of 104.33%. Stoke Therapeutics has a consensus target price of $44.17, suggesting a potential upside of 68.58%. Given MannKind’s higher possible upside, equities analysts plainly believe MannKind is more favorable than Stoke Therapeutics.

Summary

MannKind beats Stoke Therapeutics on 8 of the 14 factors compared between the two stocks.

About MannKind

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF).

About Stoke Therapeutics

Stoke Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing genetic medicines for severe diseases caused by insufficient protein production. The company uses its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) platform to design antisense oligonucleotides that can increase the expression of specific genes and potentially address the underlying causes of genetic disorders. Stoke’s leading product candidate is STK-001, an investigational antisense oligonucleotide being developed for the treatment of Dravet syndrome, a severe genetic epilepsy most commonly associated with mutations in the SCN1A gene.